Peripheral Arterial Disease Clinical Trial
Official title:
Evaluation of the Safety and Efficacy of the Paclitaxel Eluting Hemodialysis Shunt Balloon Dilatation Catheter (APERTO) in Treatment of Hemodialysis Arteriovenous Fistulae Stenosis: A Prospective, Multicenter, Randomized, Controlled Clinical Study
NCT number | NCT02962141 |
Other study ID # | APERTO-2015-01 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 2016 |
Est. completion date | June 2019 |
Verified date | August 2019 |
Source | ZhuHai Cardionovum Medical Device Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To evaluate the safety and efficacy of Paclitaxel Eluting Hemodialysis Shunt Balloon Dilatation Catheter (APERTO) compared with the Balloon Dilatation catheter (OHICHO II) for the treatment of Arteriovenous Fistulae Stenosis in patients undergoing hemodialysis.
Status | Completed |
Enrollment | 161 |
Est. completion date | June 2019 |
Est. primary completion date | January 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion criteria: Patients must meet all of the following criteria: - Age = 18 years and = 75 years, male or female. - Patient or legally authorized representative can understand the purpose of this clinic trial. He or She volunteers to participate in this trial and can provide written informed consent, and is willing to accept the scheduled follow-up in specific time points. - Angiography, ultrasound or clinical diagnosis shows that patients have hemodialysis access dysfunction due to stenosis lesions. - Patients with indications of the percutaneous endovascular therapy, that is, the AVF stenosis is related to hemodynamics and = 50%, and with any of the following clinical and physiological abnormalities (referred to NKF-K/DOQI guideline definitions): 1. Thrombosis in the AVF; 2. Elevated venous pressure during dialysis 3. Obvious abnormality in recirculation measurements 4. Abnormal physical examination findings 5. Unexplained decreases in dialysis dose 6. Decreased access flow - Target lesion is a de novo or restenosis. The number of target lesions is 1. - Target lesion consists of a single lesion or a multiple lesions with target lesion length = 40 mm. - Target lesion(s) is located in the reflux vein which is from the anastomosis of native arteriovenous fistula (AVF) to the distal end of subclavian vein, except the anastomosis of native AVF. - If patient has non-target lesion, it must be successfully treated using PTA before treating target lesion. - Reference vessel diameter of target lesion = 4.0 mm and = 7.0 mm by visual estimate (determined by angiography or DUS). - Hemodialysis access previously used (mature AVF) can no longer be successfully used due to insufficient shunt flow volume caused by local lumen stenosis. Exclusion criteria: Patients will be excluded if any of the following conditions applies: - Patients who have participated in another investigational drug or device trial. - Patients who have been enrolled in this trial previously. - Women of childbearing age with negative pregnancy test before procedure, and breastfeeding women. - Any major surgical procedure (such as thoracotomy, craniotomy, etc.) within 30 days prior to the procedure. - Any planned major surgical procedure (such as thoracotomy, craniotomy, etc.) within 30 days of entry into this study - Immature AVF, which cannot be used for Dialysis or has not been used successfully due to insufficient lumen diameter to ensure successfully puncture and insufficient shunt flow volume. - Patients with AVG. - AVF has been previously implanted with stent. - Lesion in AVF has been previously treated with DEB. - Target lesion is located in the anastomosis of native AVF. - Known allergies or intolerance to Paclitaxel or contrast medium. - Life expectancy < 1 year - Patients with comitans systemic lupus erythematosus and ANCA associated vasculitis. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Tongren Hospital, Capital Medical University | Beijing | |
China | The Third Xiangya Hospital of Central South University | Changsha | Hunan |
China | West China Hospital, Sichuan University | Chengdu | Sichuan |
China | Hainan General Hospital | Haikou | Hainan |
China | Sir Run Run Shaw Hospital School of Medicine, Zhejiang University | Hangzhou | Zhejiang |
China | The First Hospital of Zhejiang Province | Hangzhou | Zhejiang |
China | The First Affiliated Hospital of Nanchang University | Nanchang | Jiangxi |
China | Longhua Hospital Shanghai University of Tranditional Chinese Medicine | Shanghai | |
China | The First Hospital of Hebei Medical University | Shijiazhuang | Hebei |
Lead Sponsor | Collaborator |
---|---|
ZhuHai Cardionovum Medical Device Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary patency rate of the target lesion | Primary patency is defined as freedom from restenosis as determined by DUS Peak Systolic Velocity Ratio (PSVR) = 2.0 and freedom from clinically-driven target lesion revascularization (CD-TLR). Restenosis is defined as PSVR> 2.0 determined by independent DUS laboratory. Clinically-driven target lesion revascularization (CD-TLR) is defined as any re-intervention in target lesion (+/-5mm proximal or distal of the target lesion) determined by DUS due to clinical symptoms or dialysis indicators showing that it is unable to perform dialysis. |
at 6 month post procedure | |
Secondary | Device Success | Device Success is defined as ability of the Device to be delivered, inflated at pressure = RBP, and retrieved from the Target Lesion without burst. | intraoperative | |
Secondary | Technical Success | Technical Success is defined as the residual stenosis of the lumen diameter = 30% after treatment with either APERTO OTW or OHICHO II (compared with the referred vessel diameter of the nearest veins with no aneurysm). | intraoperative | |
Secondary | Clinical Success | Clinical Success is defined as improvement in hemodialysis access function and resumption of normal dialysis for at least one dialysis session after the index procedure. | at 1 month | |
Secondary | Procedural Success | Procedural Success is defined as technical success without the occurrence of MAE during the hospitalization or day of treatment (MAE defined here as: death, stroke, thrombotic occlusion, allergic reaction, pulmonary events (including pulmonary edema) | at 1 month | |
Secondary | MAE rates (death or stroke) | at 1 month, 3 months, 6 months, and 12 months post procedure. | ||
Secondary | The diameter stenosis rate in target lesion | The diameter stenosis (%)=100% × (1-(MLD/RVD)) | at 6 months post procedure | |
Secondary | Clinical-driven Target Lesion Revascularization (CD-TLR) | CD-TLR is defined as any re-intervention in target lesion (+/-5mm proximal or distal of the target lesion) determined by DUS due to clinical symptoms or dialysis indicators showing that it is unable to perform dialysis. | in1st, 3rd, 6th, 12th month post operation | |
Secondary | Clinical-driven Target Shunt Revascularization (CD-TSR) | Target Shunt is defined as the reflux vein, which is from the anastomotic stoma of native arteriovenous fistula (AVF) to the distal end of the subclavian vein. CD-TSR is defined as any re-intervention in target lesion due to clinical symptoms or inability to perform dialysis. |
in 1st, 3rd, 6th, 12th month post operation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Completed |
NCT02022423 -
Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease
|
N/A |